{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T16:27:51Z","timestamp":1780331271419,"version":"3.54.1"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2024M760146"],"award-info":[{"award-number":["2024M760146"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.yebeh.2025.110619","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:18:38Z","timestamp":1753402718000},"page":"110619","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Oral adverse events associated with antiseizure medications: An analysis of the FDA adverse event reporting system (FAERS) database"],"prefix":"10.1016","volume":"171","author":[{"given":"Jia","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8726-2550","authenticated-orcid":false,"given":"Jianxiong","family":"Gui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"41","key":"10.1016\/j.yebeh.2025.110619_b0005","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1146\/annurev-publhealth-040119-094318","article-title":"Disparities in access to oral health care","volume":"2","author":"Northridge","year":"2020","journal-title":"Annu Rev Public Health"},{"key":"10.1016\/j.yebeh.2025.110619_b0010","article-title":"Relationship between oral health, quality of life, and comprehensive health literacy in community-dwelling older adults. res theory","author":"Matsuo","year":"2023","journal-title":"Nurs Pract"},{"key":"10.1016\/j.yebeh.2025.110619_b0015","doi-asserted-by":"crossref","unstructured":"Fiorillo L. Oral Health: The First Step to Well-Being. Medicina (Kaunas). 2019 Oct 7;55(10).","DOI":"10.3390\/medicina55100676"},{"issue":"1","key":"10.1016\/j.yebeh.2025.110619_b0020","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1186\/s12889-023-16012-z","article-title":"The association of periodontal disease and oral health with hypertension, NHANES 2009-2018","volume":"23","author":"Li","year":"2023","journal-title":"BMC Public Health"},{"issue":"10","key":"10.1016\/j.yebeh.2025.110619_b0025","first-page":"613","article-title":"Oral manifestations of commonly prescribed drugs","volume":"102","author":"Glick","year":"2020","journal-title":"Am Fam Physician"},{"issue":"3","key":"10.1016\/j.yebeh.2025.110619_b0030","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2165\/00002018-199615030-00007","article-title":"Gingival enlargement induced by drugs","volume":"15","author":"Brunet","year":"1996","journal-title":"Drug Saf"},{"issue":"1","key":"10.1016\/j.yebeh.2025.110619_b0035","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1834-7819.1998.tb00145.x","article-title":"Minocycline and oral pigmentation","volume":"43","author":"Cockings","year":"1998","journal-title":"Aust Dent J"},{"issue":"34","key":"10.1016\/j.yebeh.2025.110619_b0040","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","article-title":"Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors","volume":"23","author":"Bamias","year":"2005","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.yebeh.2025.110619_b0045","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1001\/jama.2022.3880","article-title":"Antiseizure medications for adults with epilepsy: a review","volume":"327","author":"Kanner","year":"2022","journal-title":"J Am Med Assoc"},{"issue":"10172","key":"10.1016\/j.yebeh.2025.110619_b0050","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0140-6736(18)32596-0","article-title":"Epilepsy in adults","volume":"393","author":"Thijs","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.yebeh.2025.110619_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2023.109283","article-title":"Mining and analysis of adverse drug reactions associated with perampanel based on FAERS database","volume":"145","author":"Liu","year":"2023","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2025.110619_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajp.2023.103828","article-title":"Adverse events of epidiolex: a real-world drug safety surveillance study based on the FDA adverse event reporting system (FAERS) database","volume":"90","author":"Zhou","year":"2023","journal-title":"Asian J Psychiatr"},{"key":"10.1016\/j.yebeh.2025.110619_b0065","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1339721","article-title":"A real-world pharmacovigilance study of FDA adverse event reporting system events for diazepam","volume":"15","author":"He","year":"2024","journal-title":"Front Pharmacol"},{"issue":"12","key":"10.1016\/j.yebeh.2025.110619_b0070","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1111\/epi.14591","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs: an analysis of the US food and drug administration adverse event reporting system","volume":"59","author":"Borrelli","year":"2018","journal-title":"Epilepsia"},{"issue":"8","key":"10.1016\/j.yebeh.2025.110619_b0075","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1111\/epi.16596","article-title":"Thrombocytopenia in pediatric patients on concurrent cannabidiol and valproic acid","volume":"61","author":"McNamara","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2025.110619_b0080","article-title":"Sodium valproate versus phenytoin monotherapy for epilepsy: an individual participant data review","author":"Nevitt","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"10.1016\/j.yebeh.2025.110619_b0085","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s40263-022-00955-9","article-title":"Psychobehavioural and cognitive adverse events of anti-seizure medications for the treatment of developmental and epileptic encephalopathies","volume":"36","author":"Strzelczyk","year":"2022","journal-title":"CNS Drugs"},{"key":"10.1016\/j.yebeh.2025.110619_b0090","doi-asserted-by":"crossref","DOI":"10.4103\/jpgm.jpgm_1059_21","article-title":"Levetiracetam-induced gingival hyperplasia","author":"James","year":"2022","journal-title":"J Postgrad Med"},{"key":"10.1016\/j.yebeh.2025.110619_b0095","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.seizure.2023.07.003","article-title":"Real-world safety of Lacosamide: a pharmacovigilance study based on spontaneous reports in the FDA adverse event reporting system","volume":"110","author":"Liu","year":"2023","journal-title":"Seizure"},{"issue":"10","key":"10.1016\/j.yebeh.2025.110619_b0100","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1007\/s00431-023-05146-2","article-title":"Drug-associated kidney injury in children: a disproportionality analysis of the FDA adverse event reporting system","volume":"182","author":"Zhang","year":"2023","journal-title":"Eur J Pediatr"},{"issue":"8","key":"10.1016\/j.yebeh.2025.110619_b0105","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.yebeh.2025.110619_b0110","doi-asserted-by":"crossref","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"10.1016\/j.yebeh.2025.110619_b0115","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.yebeh.2025.110619_b0120","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","article-title":"Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database","volume":"25","author":"Szarfman","year":"2002","journal-title":"Drug Saf"},{"issue":"4","key":"10.1016\/j.yebeh.2025.110619_b0125","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/j.1528-1167.2010.02966.x","article-title":"The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials","volume":"52","author":"Zaccara","year":"2011","journal-title":"Epilepsia"},{"issue":"5","key":"10.1016\/j.yebeh.2025.110619_b0130","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00406-002-0376-3","article-title":"A combination of carbamazepine\/tiapride in outpatient alcohol detoxification. results from an open clinical study","volume":"252","author":"Soyka","year":"2002","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"2","key":"10.1016\/j.yebeh.2025.110619_b0135","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.oooo.2014.10.027","article-title":"World Workshop on Oral Medicine VI: clinical implications of medication-induced salivary gland dysfunction","volume":"120","author":"Aliko","year":"2015","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"issue":"6","key":"10.1016\/j.yebeh.2025.110619_b0140","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1016\/j.ajpath.2015.02.004","article-title":"Prevention of phenytoin-induced gingival overgrowth by lovastatin in mice","volume":"185","author":"Assaggaf","year":"2015","journal-title":"Am J Pathol"},{"issue":"5","key":"10.1016\/j.yebeh.2025.110619_b0145","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/odi.12651","article-title":"Phenytoin-induced gingival overgrowth caused by death receptor pathway malfunction","volume":"23","author":"Takeuchi","year":"2017","journal-title":"Oral Dis"},{"issue":"6","key":"10.1016\/j.yebeh.2025.110619_b0150","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1440-1797.2007.00884.x","article-title":"Conversion of cyclosporine to tacrolimus in stable renal allograft recipients: quantification of effects on the severity of gingival enlargement and hirsutism and patient-reported outcomes","volume":"12","author":"Walker","year":"2007","journal-title":"Nephrology (Carlton)"},{"issue":"1","key":"10.1016\/j.yebeh.2025.110619_b0155","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/jhh.2013.47","article-title":"Calcium channel blocker-induced gingival enlargement","volume":"28","author":"Livada","year":"2014","journal-title":"J Hum Hypertens"},{"issue":"6","key":"10.1016\/j.yebeh.2025.110619_b0160","first-page":"e610","article-title":"Is dental plaque the only etiological factor in Amlodipine induced gingival overgrowth? a systematic review of evidence","volume":"10","author":"Gaur","year":"2018","journal-title":"J Clin Exp Dent"},{"key":"10.1016\/j.yebeh.2025.110619_b0165","doi-asserted-by":"crossref","first-page":"420","DOI":"10.2174\/1874210601610010420","article-title":"Are pediatric antibiotic formulations potentials risk factors for dental caries and dental erosion?","volume":"10","author":"Valinoti","year":"2016","journal-title":"Open Dent J"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505025003592?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505025003592?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:14:42Z","timestamp":1778616882000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505025003592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":33,"alternative-id":["S1525505025003592"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2025.110619","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral adverse events associated with antiseizure medications: An analysis of the FDA adverse event reporting system (FAERS) database","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2025.110619","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110619"}}